[Surgical management of orbital malignant melanoma: our experience and a report of three cases].
OBJECTIVE
The aim of this study is to illustrate our personal experience concerning the diagnostic and therapeutic management of primary and secondary orbital melanomas.


METHODS
Nine patients (five men and four women) with a histological diagnosis of orbital malignant melanoma were surgically treated in our department during the last 10 years (1995 - 2005).


RESULTS
All the patients had a unilateral orbital malignant melanoma. A primary tumour was diagnosed in one case. There was metastatic orbital localisation of a cutaneous malignant melanoma in two cases. In six cases, a secondary melanoma originated from the uveal tract (three cases), conjunctiva (two cases), or paranasal sinuses (one case). All the patients underwent surgical treatment of the tumour (exenteration in 5 cases; subtotal exenteration in one case; subtotal excision in two cases; and craniofacial resection in one case) combined with immunotherapy in one case. The median age at surgery was 66 years, with a mean postoperative follow-up of 17 +/- 14 months. Four patients died of widespread dissemination of the melanoma after a mean time of 13 +/- 7 months. Two more patients died of causes other than melanoma. Three patients were still living at 9, 33 and 45 months after surgery. None of the patients presented with a local relapse of the melanoma during follow-up.


CONCLUSIONS
Although different approaches have been proposed, the prognosis of orbital melanoma remains poor. In our experience too, the patients with longest survival were those whose tumours were exenterated.
Poli
T
T
Department of Ophthalmologic and Cervical-Facial Sciences, Parma University, Via Gramsci 14, Parma, Italy.
Mora
P
P
Reichegger
V
V
Ricci
R
R
Corradi
D
D
Gandolfi
S A
SA
Sesenna
E
E
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D003230:Conjunctival Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D008866:Microsurgery; D008875:Middle Aged; D009915:Orbit / Q000473:pathology; D017233:Orbit Evisceration; D009918:Orbital Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D010255:Paranasal Sinus Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D012878:Skin Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D014057:Tomography, X-Ray Computed; D014604:Uveal Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*